🔗 Share this article

The recently developed medications for gonorrhoea in decades are being viewed as a "huge turning point" in the effort against increasingly resistant strains of the pathogen, according to scientists.

A Worldwide Challenge

Cases of gonorrhoea are on the rise worldwide, with data suggesting in excess of 82 million new cases annually. Notably increased rates are reported in the African continent and countries within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an important and timely advancement in the reality of increasing worldwide cases, the spread of superbugs and the extremely scarce treatment choices currently available.”

Health officials are deeply concerned about the rise in antibiotic-resistant strains. The World Health Organization has designated it as a "high-priority threat". Recent surveillance revealed that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Receive Clearance

Zoliflodacin, alternatively called a brand name, was cleared by the American regulatory agency in mid-December for use against gonorrhoea. This disease can lead to significant complications, including infertility. Scientists believe that specific application of this new drug will help slow the development of resistance.

Another new antibiotic, developed by the drugmaker GSK, was also approved in concurrent days. This treatment, which is also used to treat UTIs, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

This new treatment was the result of a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to see it through.

“This milestone represents a huge turning point in the treatment of multidrug-resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Research Study Results and Global Access

Based on results detailed in a major medical journal, zoliflodacin cured more than 90% of uncomplicated infections. This establishes an comparable level with the existing first-line therapy, which involves two antibiotics. The study enrolled over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the rights to make available and distribute the drug in a wide range of low-income and middle-income countries.

Medical professionals treating patients have voiced hope. Access to a single-dose, oral treatment such as this is described as a "game-changer" for gonorrhoea control. This is considered vital to reduce the burden of the disease for people and to prevent the spread of extremely resistant gonorrhoea globally.